On November 17, Caris Life Sciences, Inc. fell 4.07% in Regular Trading, trading at $20.155 per share, with turnover of $10.9942 million.
The move followed continued post-earnings selling pressure after the company reported third-quarter results above expectations and raised full-year revenue guidance, yet investors remained cautious on valuation and growth durability.
Caris Life Sciences, Inc. previously reported Q3 EPS of $0.05, above expectations of about $0.03 to $0.04, while revenue rose to $275.4 million from $216.8 million a year earlier and exceeded the roughly $255.4 million forecast. The company also lifted full-year revenue guidance to $1.04 billion to $1.05 billion from $1.03 billion to $1.04 billion previously. Even so, EPS was below $0.08 a year earlier, and the latest trading showed that post-earnings pressure had not fully faded.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments